Clinical Trials Directory

Trials / Completed

CompletedNCT03889509

A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis

Status
Completed
Phase
Study type
Observational
Enrollment
63 (actual)
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

This protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.

Detailed description

A systematic review was conducted to determine the risk/associated factors for pulmonary arterial hypertension in systemic sclerosis, including clinical/disease characteristics, antibody status, test results and biomarkers. The frequency of publications featuring a risk/association were reported. The following databases were searched: Medline, EMBASE, the Cochrane Library, Web of Science, and SCOPUS. The following search terms were used: ( essential pulmonary hypertension or familial primary pulmonary hypertension or hypertension, pulmonary or hypertension,lung or hypertensive pulmonary vascular disease or idiopathic pulmonary arterial hypertension or lung arterial hypertension or lung artery hypertension or lung hypertension or primary pulmonary hypertension or pulmonary arterial hypertension or pulmonary artery hypertension or pulmonary fixed hypertension or pulmonary hypertensive disease or pulmonary hypertensive diseases or pulmonary hypertensive disorder or pulmonary hypertensive disorders ) AND ( generalised scleroderma or generalized scleroderma or progressive scleroderma or progressive sclerodermia or progressive sclerosis,systemic or progressive systemic sclerosis or scleroderma, generalised or scleroderma, generalized or scleroderma, progressive or scleroderma, systemic or sclerosis,progressive systemic or sclerosis,systemic or sclerosis,systemic progressive or systemic progressive sclerosis or systemic scleroderma or systemic sclerosis,progressive or scleroderma, limited or limited scleroderma or limited cutaneous scleroderma or diffuse scleroderma or progressive diffuse scleroderma or scleroderma, diffuse ) AND ( prevalence or prevalence study or relative risk or risk factors )

Conditions

Timeline

Start date
2018-03-01
Primary completion
2020-03-01
Completion
2021-03-01
First posted
2019-03-26
Last updated
2022-08-19

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03889509. Inclusion in this directory is not an endorsement.